Establishment and implementation of Cancer Genomic Medicine in Japan
Authors:
Open Access
- 1 December 2020
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 112 (3) , 970-977
Abstract
Approximately 1 in 2 Japanese people are estimated to be diagnosed with cancer during their lifetime. Cancer still remains the leading cause of death in Japan, therefore the government of Japan has decided to develop a better cancer control policy and launched the Cancer Genomic Medicine (CGM) program. The Ministry of Health, Labour, and Welfare (MHLW) held a consortium at their headquarters with leading academic authorities and the representatives of related organizations to discuss ways to advance CGM in Japan. Based on the report of the consortium, the CGM system under the national health insurance system has gradually been realized. Eleven hospitals were designated in February 2018 as core hospitals for CGM; subsequently, the MHLW built the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) as an institution to aggregate and manage genomic and clinical information on cancer patients, and support appropriate secondary use of the aggregated information to develop research aimed at medical innovation. As the first step in Japan's CGM in routine practice, in June 2019 the MHLW started reimbursement of 2 types of tumor profiling tests for advanced solid cancer patients using the national insurance system. Japan's CGM has swiftly been spreading nationwide with the collaboration of 167 hospitals and patients. The health and research authorities are expected to embody personalized cancer medicine and promote CGM utilizing state‐of‐the‐art technologies.Keywords
This publication has 6 references indexed in Scilit:
- Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based studyCancer Science, 2019
- Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin‐fixed paraffin‐embedded specimensCancer Science, 2019
- Application of Cell-free DNA Analysis to Cancer TreatmentNew England Journal of Medicine, 2018
- Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)Cancer Science, 2018
- Feasibility study of cancer genome alterations identified by next generation sequencing: ABC studyJapanese Journal of Clinical Oncology, 2018
- Clinical sequencing using a next‐generation sequencing‐based multiplex gene assay in patients with advanced solid tumorsCancer Science, 2017